EAM
MGX icon

Eventide Asset Management’s Metagenomi Therapeutics MGX Stock Holding History

Eventide Asset Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-583,041
Closed -$2.38M – 196
2024
Q2 		$2.38M Hold
583,041
– – 0.04% 145
2024
Q1 		$6.15M Buy
+583,041
New +$6.7M 0.1% 132

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eventide Asset Management's MGX Position: Q3 2024 in Review

Eventide Asset Management sold out of Metagenomi Therapeutics (MGX) in Q3 2024, closing a stake of 583,041 shares — an estimated $2.38M sold.

Eventide Asset Management first reported a position in MGX in Q1 2024 and held it in 2 quarters. The position peaked at $6.15M in Q1 2024. 67 funds tracked by Wall St. Rank hold MGX as of Q3 2024.

  • Eventide Asset Management reported no remaining Metagenomi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eventide Asset Management sold 583,041 Metagenomi Therapeutics shares in Q3 2024, an estimated $2.38M.
  • Eventide Asset Management first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 2 quarters.
  • Eventide Asset Management's Metagenomi Therapeutics position peaked at $6.15M in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2024.

Based on Eventide Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.